1. Home
  2. AKBA vs EAF Comparison

AKBA vs EAF Comparison

Compare AKBA & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.38

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$6.21

Market Cap

429.4M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
EAF
Founded
2007
1886
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
380.4M
429.4M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
AKBA
EAF
Price
$1.38
$6.21
Analyst Decision
Strong Buy
Hold
Analyst Count
6
4
Target Price
$5.75
$11.75
AVG Volume (30 Days)
2.5M
244.8K
Earning Date
05-07-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$504,134,000.00
Revenue This Year
N/A
$4.25
Revenue Next Year
N/A
$12.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$0.55
52 Week High
$4.08
$20.32

Technical Indicators

Market Signals
Indicator
AKBA
EAF
Relative Strength Index (RSI) 51.06 40.92
Support Level $1.30 $5.90
Resistance Level $1.55 $7.47
Average True Range (ATR) 0.07 0.47
MACD 0.00 0.33
Stochastic Oscillator 50.70 88.67

Price Performance

Historical Comparison
AKBA
EAF

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

Share on Social Networks: